Biologic beats methotrexate for early RA

Tocilizumab as an initial therapy offers a better chance of remission than the standard treatment of methotrexate monotherapy in early rheumatoid arthritis, a Dutch clinical trial shows.

The two-year U-Act-Early trial compared 317 patients, diagnosed with RA in the preceding year, across three treatment arms: tocilzumab monotherapy, methotrexate monotherapy or a combination of the two.

Eighty six percent of patients in